Acuvue Theravision With Ketotifen is a drug owned by Johnson And Johnson Vision Care Inc. It is protected by 2 US drug patents filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 27, 2030. Details of Acuvue Theravision With Ketotifen's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9962376 | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(5 years from now) | Active |
| US9474746 | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Acuvue Theravision With Ketotifen's patents.
Latest Legal Activities on Acuvue Theravision With Ketotifen's Patents
Given below is the list of recent legal activities going on the following patents of Acuvue Theravision With Ketotifen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Apr, 2024 | US9474746 |
| Email Notification Critical | 06 Mar, 2024 | US9962376 |
| Mail Patent eCofC Notification | 05 Mar, 2024 | US9962376 |
| Recordation of Patent eCertificate of Correction | 05 Mar, 2024 | US9962376 |
| Patent eCofC Notification | 05 Mar, 2024 | US9962376 |
| Email Notification Critical | 05 Mar, 2024 | US9962376 |
| Post Issue Communication - Certificate of Correction | 14 Feb, 2024 | US9962376 |
| Email Notification Critical | 01 Feb, 2024 | US9962376 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 31 Jan, 2024 | US9962376 |
| Mail-Petition Decision - Granted | 30 Jan, 2024 | US9962376 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Acuvue Theravision With Ketotifen and ongoing litigations to help you estimate the early arrival of Acuvue Theravision With Ketotifen generic.
Acuvue Theravision With Ketotifen's Litigations
Acuvue Theravision With Ketotifen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 18, 2013, against patent number US9962376. The petitioner , challenged the validity of this patent, with Ranganath R. Raja et al as the respondent. Click below to track the latest information on how companies are challenging Acuvue Theravision With Ketotifen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9962376 | November, 2013 |
Decision
(19 Apr, 2016) | Ranganath R. Raja et al | |
FDA has granted some exclusivities to Acuvue Theravision With Ketotifen. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Acuvue Theravision With Ketotifen, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Acuvue Theravision With Ketotifen.
Exclusivity Information
Acuvue Theravision With Ketotifen holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Acuvue Theravision With Ketotifen's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2025 |
US patents provide insights into the exclusivity only within the United States, but Acuvue Theravision With Ketotifen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Acuvue Theravision With Ketotifen's family patents as well as insights into ongoing legal events on those patents.
Acuvue Theravision With Ketotifen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Acuvue Theravision With Ketotifen's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 27, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Acuvue Theravision With Ketotifen Generic API suppliers:
Ketotifen Fumarate is the generic name for the brand Acuvue Theravision With Ketotifen. 5 different companies have already filed for the generic of Acuvue Theravision With Ketotifen, with Alcon Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Acuvue Theravision With Ketotifen's generic
About Acuvue Theravision With Ketotifen
Acuvue Theravision With Ketotifen is a drug owned by Johnson And Johnson Vision Care Inc. Acuvue Theravision With Ketotifen uses Ketotifen Fumarate as an active ingredient. Acuvue Theravision With Ketotifen was launched by Johnson Johnson Visn in 2022.
Approval Date:
Acuvue Theravision With Ketotifen was approved by FDA for market use on 25 February, 2022.
Active Ingredient:
Acuvue Theravision With Ketotifen uses Ketotifen Fumarate as the active ingredient. Check out other Drugs and Companies using Ketotifen Fumarate ingredient
Dosage:
Acuvue Theravision With Ketotifen is available in drug-eluting contact lens form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 19MCG BASE | DRUG-ELUTING CONTACT LENS | Discontinued | OPHTHALMIC |